More recently, the European Leukemia Net (ELN) classified AML based on specific prognostic cytogenetic and molecular features that are present in the leukemic cells, including mutations in NPM1, FLT3 and TP53 into three risk categories for relapse (favorable, intermediate or adverse risk), which has direct implications for therapeutic decisions [4]. Here, NPM1 is linked to acute myeloid leukemia.